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Copyright © 2008 AHC We conducted a clinicopathologic study on protein and mRNA levels of thymidylate synthase
(TS), thymidine phosphorylase (TP) and orotate phosphoribosyl transferase (OPRT) using
biopsy tissue specimens before treatment. The mRNA levels have been measured in tumor
cells microdissected from paraffin-embedded specimens (Danenberg Tumor Profile method:
DTP method). We studied the mRNA and protein expression as effect predictive factors in
chemotherapy. The subjects consisted of 20 cases of untreated oral squamous cell carci-
noma who had undergone chemotherapy with TS-1 (16 males and 4 females, tongue in 8
cases, upper gingiva in 3 cases, lower gingiva in 3 cases, buccal mucosa in 5 cases and
floor of the mouth in 1 case). TS gene expressions of the responders were lower than those
for the nonresponders. Furthermore, regarding males who were less than 70 years of age,
stage I and II, well differentiated type and tongue, TS mRNA expression of the responders
were lower than that for the nonresponders. The mRNA expression of OPRT for the male
responders was lower than that for the nonresponders. No remarkable difference was ob-
served by immunohistochemistry. In this study, the measurement of the TS levels using the
DTP method may potentially act as a predictive factor of antitumor effectiveness.
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I. Introduction
In anticancer drugs, the therapeutically effective blood
concentration and the toxicity-development blood concen-
tration are closely related. A therapeutic plan that considers
the prognostic factors and the effective predictive factors is
required in the selection of patients in whom a good re-
sponse can be expected before implementing effective and
safe cancer therapy. In advanced oral cancer, radiation and
chemotherapy are used concomitantly with surgical therapy,
and as part of chemotherapy, 5-fluorouracil (5-FU) is one of
the anticancer drugs that is most widely used for head and
neck cancer. Thymidylate synthase (TS), thymidine phos-
phorylase (TP), orotate phosphoribosyl transferase (OPRT)
are referred to as 5-FU-related enzymes, and it has been in-
dicated that the enzyme activity and enzyme content may be
correlated with the antitumor effects of 5-FU-based drugs.
Recently, the relationship between the expression of
the metabolic enzymes of 5-FU in tumors and anticancer
efficacy has been studied [6, 8, 13, 18, 19]; however, the
mRNA of metabolic enzymes that have been measured in
specimens includes not only the mRNA expression level of
tumor cells but also the entire tumor tissue, including the
interstitium, and the number of specimens is also limited.
There have been relatively few reports in which the level ofOgiuchi et al. 40
expression of the mRNA in TS, TP, and OPRT has been
measured in tumor tissue using specimens of formalin-fixed
paraffin-embedded slices of biopsy tissue obtained using
laser capture microdissection in oral cancer as samples
(Danenberg Tumor Profile method: DTP method [5, 16]).
This report describes the findings of a clinicopatholog-
ical study while also investigating the mRNA expression
with laser capture microdissection and protein expression of
TS, TP and OPRT.
II. Patients and Methods
The subjects consisted of 20 cases of untreated oral
squamous cell carcinoma who had undergone chemotherapy
and surgery at Oral and Maxillofacial Surgery Department,
Tokyo Women’s Medical University Hospital from January
1998 to September 2006, including 16 males and 4 females.
Their ages ranged from 52 to 80, with an average of 69.6.
The primary site included the tongue in 8 cases, upper gin-
giva in 3 cases, lower gingiva in 3 cases, buccal mucosa in 5
cases, and the floor of the mouth. As for the stages of pro-
gression, 4 cases were stage I, 14 cases were stage II, 1 case
was stage III, and 1 case was stage IV. As for the degree of
differentiation, 15 cases were of the well differentiated type
and 5 cases were of the moderately differentiated type.
Formalin-fixed paraffin-embedded slice specimens
were prepared from biopsy tissue specimens before treat-
ment of the oral squamous cell cancer, and 4 μm sliced strips
were used for immunostaining and 10 μm sliced strips for
the DTP method. We conducted a clinicopathologic study of
the mRNA expression and the protein expression of TS, TP
and OPRT, while also evaluating the relationship regarding
the therapeutic effects of chemotherapy.
TS-1 (Taiho Pharmaceutical Co, Ltd. Tokyo Japan)
was given for 14 days as neoadjuvant chemotherapy [17].
The dosage of TS-1 was selected as follows: in a patient with
body surface area (BSA) (<1.25 m2, 80 mg/day; 1.25 m2≤
BSA <1.5 m2, 100 mg/day; 1.5 m2≥ BSA, 120 mg/day).
The effect on the tumors was determined 7 days after the
administration of TS-1 was completed and the evaluation
method was implemented while observing the therapeutic
effect evaluation standard according to the General Rules
for Clinical Studies on Head and Neck Cancer [1]. There
were 2 complete responses, 8 partial responses and 10 cases
with no change. Both the complete responses and the partial
responses were considered to be responders.
This study was approved by the Institutional Review
Board of the Tokyo Women’s Medical University.
Danenberg Tumor Profile
A representative formalin-fixed, paraffin-embedded tu-
mor specimen obtained from primary tumors was selected
by a pathologist after examining the haematoxylin-eosin-
stained slides. Ten μm thick sections were stained with nu-
clear fast red to enable the visualization of histology for laser
capture microdissection (PALM Microlaser Technologies
AG, Munich, Germany) (Fig. 1), which was performed to
ensure that only tumor cells were studied. Microdissected
samples were collected into a microcentrifuge tube. Six hun-
dred μl of xylene was added to each tube. After centrifuga-
tion for 7 min at 14000 rpm, the supernatant was discarded,
and the washing step was repeated three times. The deparaf-
finised materials were rehydrated in xylene:ethanol:water at
the following ratios (95:95:5, 95:90:10, 95:80:20, 95:75:25,
and 95:70:30). After each step, the rehydration medium was
removed after centrifugation for 7 min at 14000 rpm. After
discarding the last supernatant, the pelleted sections were
resolved in 70% ethanol. Four hundred μl of buffer (4 M
guanidine isothiocyanate solution including 0.5% sarcosine
and 8 μl 1 M DTT) were then added to the dried tissue
and homogenised mechanically. For RNA demodification,
homogenates were heated at 95°C for 30 min. RNA was
extracted from homogenates by addition of 50 μl of 2 M
sodium acetate (pH 4.0), 500 μl of water-saturated phenol,
and 100 μl of chloroform-isoamyl mixture (49:1). RNA
was recovered from the water phase by isopropanol pre-
Fig. 1. Laser captured microdissection of cancer cell, Hematoxylin-eosin stain (A) After laser captured microdissection of cancer cell (B).TS, TP and OPRT Levels as a Predictive Factor of Chemotherapy 41
cipitation and transferred to a new tube and precipitated
with 10 μl glycogen and 400 μl isopropanol for 30 min at
−20°C. After centrifuging for 7 min at 14000 rpm, the pellet
was washed with 500 μl 75% ethanol. After drying, the
pellet was dissolved in 50 μl 5 mM Tris-HCL (pH 8.0). Re-
verse transcription was carried at 39°C for 45 min using
400U of MMLV reverse transcriptase, 1×first strand buffer,
0.04 μl random hexamers, 10 mM DTT, and 1 mM deoxy-
nucleoside triphosphate. The target cDNA sequences were
amplified by quantitative PCR using a fluorescence-based
real-time detection method (ABI PRISM 7900 Sequence
Detection System (Taqman), Applied Biosystems, Foster
City, CA, USA). Polymerase chain reaction was carried for
each gene of interest, and β-actin was used as an internal
reference gene. The 25 μl PCR reaction mixture contained
600 nmol/l of each primer, 200 nmol/l each of dATP, dCTP,
and dGTP, 400 μmol/l dUTP, 5.5 mmol/l MgCl2, and
1×TaqMan buffer A containing a reference dye. The prim-
ers and probe sequences used were as follows: TS primers:
GCCTCGGTGTGCCTTTCA and CCCGTGATGTGCGC-
AAT, probe 6FAM-TCGCCAGCTACGCCCTGCTCA; TP
primers: CCTGCGGACGGAATCCT and GCTGTGATG-
AGTGGCAGGCT, probe 6FAM-CAGCCAGAGATGTG-
ACAGCCACCGT; OPRT primers TAGTGTTTTGGAA-
ACTGTTGAG GTT and CTTGCCTCCCTGCTCTCTGT,
probe 6FAM-TGGCATCAGTGACCTTCAAGCCCTCCT;
β-actin primers: TGAGCGCGGCTACAGCTT and TCCT-
TAATGTCACGCACGATTT probe 6FAM-ACCACCAC-
GGCCGAGCGG.
The PCR conditions were 50°C for 10 sec and 95°C for
10 min, followed by 42 cycles at 95°C for 15 sec and 60°C
for 1 min. The relative gene expression of TS, TP and OPRT
was determined based on the threshold cycles of each gene
in relation to the threshold cycle of the corresponding inter-
nal standard β-actin. Gene expressions were quantified as
the ratio between two measurements (gene of interest/β-
actin).
Immunohistochemistry
Multiple 4 μm-thick sections of the paraffin-embedded
tissue were examined for immunohistochemistry. The pri-
mary antibodies utilized in immunohistochemistry were
rabbit polyclonal antibodies specific for TS (diluted 1:500),
OPRT (diluted 1:500) a mouse monoclonal antibodies spe-
cific for TP (diluted 1:500). Prior to immunostaining, sec-
tions (TS, OPRT) were processed for microwaving for 23
min in 10 mM citrate buffer (pH 6.0). Sections were depar-
affinized, rehydrated, quenched for 20 min at 4°C with 3%
hydrogen peroxide for inhibiting endogenous peroxidase ac-
tivity, rinsed in 150 mM phosphate-buffered saline (pH 7.6),
incubated overnight at 4°C with the primary antibodies.
Immunoreaction product deposits with the primary anti-
bodies were visualized using an Envision kit (Dako). 3,3'-
Diaminobenzidine tetrahydrochloride (Dojin, Kumamoto,
Japan) solution was used as the chromogen, and hematoxy-
lin was used as the counterstain. The sections from which
the primary antibodies were omitted served as negative reac-
tion controls. The labeling indices for TS, TP and OPRT
proteins were determined by calculating the percentage of
immunoreactive cells in more than 500 cancer cells (Fig. 2).
Fig. 2. Immunohistochemical staining for TS×100 (A), TS×200 (B), TP×100 (C), TP×200 (D) and OPRT×100 (E), OPRT×200 (F). Staining is
observed in the cytoplasm of cancer cells.Ogiuchi et al. 42
Statistical analysis
Significance was assessed by Mann-Whitney’s U-test.
P values of less than 0.05 were considered to be significant.
III. Results
The characteristics of the patients are summarized in
Table 1. In all 20 cases, laser capture microdissection of
cancer cells was possible and the mRNA of TS, TP and
OPRT could be measured. The median value of the mRNA
expression was 3.9 for TS, 51.8 for TP and 1.4 for OPRT,
which was selected for a cutoff value to separate high and
low levels of expression.
TS, TP, and OPRT protein were observed in the cyto-
plasm by immunostaining, and the median value of the pro-
tein expression was 12.4% for TS, 16.9% for TP, and 17.2%
for OPRT, which was selected for a cutoff value to separate
high and low levels of expression. The mRNA expression of
TS in the response group was low in 9 of 10 cases, and the
protein expression was low in 5 of 10 cases. The mRNA
expression of TP in the response group was low in 6 of 10
cases, and the protein expression was low in 5 of 10 cases.
The mRNA expression of OPRT in the response group was
low in 9 of 10 cases, and the protein expression was low in
8 of 10 cases.
Regarding the gender, the age, the clinical stage, the
degree of differentiation and the site, TS, TP and OPRT
mRNA and protein expression are shown in Table 2. The TP
mRNA expression in patients who were less than 70 years of
age was lower than that in patients older than 71 years of age
(p<0.05). There was no remarkable difference for TS and
OPRT.
mRNA expression of TS, TP and OPRT according to
response is shown in Figure 3. The average values of TS
mRNA expression were 2.6 and 5.3 for responders and non-
responders, respectively, and TS was therefore lower in the
responders (p<0.05). The average values of TP mRNA
expression were 53.9 and 49.6 for responders and non-
responders, respectively. The average values of OPRT
mRNA expression were 0.9 and 1.9 for responders and
nonresponders, respectively. There were no remarkable
differences for TP and OPRT.
Protein expression of TS, TP and OPRT according to
response is shown in Figure 4. The average values of TS
protein expression were 10.9% and 14% for responders and
nonresponders, respectively. The average values of TP pro-
tein expression were 22.4% and 11.5% for responders and
nonresponders, respectively. The average values of OPRT
protein expression were 7.8% and 26.5% for responders and
nonresponders, respectively. There were no remarkable dif-
ferences for TS, TP and OPRT.
Furthermore, response and nonresponse findings were
studied after the patients were categorized by gender, age,
clinical stage, degree of differentiation and site (Table 3).
Table 1. Patient clinical characteristics and mRNA and protein expression of TS, TP and OPRT
TS: thymidylate synthase, TP: thymidine phosphorylase, OPRT: orotate phosphoribosyl transferase.
CR: complete response, PR: partial response, NC: no change
Case Gender Age Site Stage Differentiation
TS TP OPRT
response mRNA/
β-actin
Protein 
(%)
mRNA/
β-actin
Protein 
(%)
mRNA/
β-actin
Protein 
(%)
1 M 70 Tongue II Well 1.2 14 42.2 55 0.8 1 CR
2 F 66 Buccal mucosa I Well 3.3 17 51.6 18 0.9 1 CR
3 M 56 Tongue II Well 1.7 19 34.3 8 1 1 PR
4 M 66 Tongue II Well 2 1 47 8 1.1 1 PR
5 M 71 Buccal mucosa II Moderately 4.3 14 61.6 40 0.7 17 PR
6 M 65 Buccal mucosa II Well 1.2 22 22.7 3 1.2 26 PR
7 M 76 Buccal mucosa II Well 2.5 2 53.1 4 0.5 2 PR
8 M 76 Buccal mucosa II Well 3.1 3 53.2 16 0.7 4 PR
9 F 84 Upper gingiva II Well 3.5 12 123 44 0.9 24 PR
10 F 77 Upper gingiva II Well 3.2 5 51.3 28 1.8 1 PR
11 M 52 Tongue I Well 3.5 29 131 20 2.6 90 NC
12 F 75 Tongue II Well 2.3 7 42.8 1 0.4 1 NC
13 M 66 Tongue I Moderately 7.7 13 31.2 8 2.1 21 NC
14 M 66 Tongue I Moderately 2.1 1 24.9 1 0.75 5 NC
15 M 71 Tongue II Well 10.8 15 25.8 1 2.7 1 NC
16 M 64 Upper gingiva II Moderately 8.8 13 23 11 2.49 41 NC
17 M 75 Lower gingiva IV Well 3.7 31 84.9 50 0.9 90 NC
18 M 67 Lower gingiva III Well 6.4 10 26.5 3 1.43 3 NC
19 M 80 Lower gingiva II Well 3 1 79.5 18 1.04 1 NC
20 M 69 Floor of mouth II Moderately 4.8 20 27.3 2 5.1 12 NCTS, TP and OPRT Levels as a Predictive Factor of Chemotherapy 43
mRNA expression of TS and OPRT for the male responders
was significantly lower than that for the nonresponders. TS
mRNA expression with the responders who were less than
70 years of age were significantly lower than that for the
nonresponders. TS mRNA expression of stage I, II with the
responders were significantly lower than that for the non-
responders. TS mRNA expression of responders with a
well differentiated type was significantly lower than that for
the nonresponders. TS mRNA expression of the responders
in the tongue was significantly lower than that for the non-
responders. There was no remarkable difference in the pro-
tein levels of TS, TP and OPRT by immunostaining.
Table 2. Patient and tumor characteristics according to level of mRNA and protein expression of TS, TP and OPRT
Mann-Whitney’s U-test *p<0.05, TS: thymidylate synthase, TP: thymidine phosphorylase, OPRT: orotate phosphoribosyl transferase.
Number of 
patients
TS TP OPRT
mRNA/β-actin Protein (%) mRNA/β-actin Protein (%) mRNA/β-actin Protein (%)
Gender
Male 16 4.1 13 48 15.3 1.5 19.8
Female 4 3.1 10.3 67.1 22.8 1 6.75
Age (years)
≤70 11 3.8 14.6 41.9 
*
12.5 1.7 20.1
>70 9 4 10 63.8 23 1 15.7
Clinical stage
I=4 18 3.8 11.5 51.4 16 1.4 13.9
II=14
III=1 2 5 20.5 55.6 26.5 1.1 46.5
IV=1
WHO classification
Well 15 3.4 12.5 57.9 18.5 1.2 16.5
Moderately 5 5.5 12 33.6 12.4 2.2 19.2
Site
Tongue 8 3.9 12.3 47.4 12.8 1.4 15.1
Upper gingiva 3 5.1 10 65.6 27.7 1.7 22
Lower gingiva 3 4.3 14 63.5 23.6 1.1 31.3
Buccal mucosa 5 2.9 11.6 48.4 16.2 0.8 10
Floor of mouth 1 4.8 20 27.3 2 5.1 12
Fig. 3. Expression of mRNA of TS, TP, and OPRT according to response, TS was significantly lower in the response group (Mann-Whitney
U test).Ogiuchi et al. 44
IV. Discussion
It is generally believed that there are three phosphory-
lation pathways for 5-FU. One is the 5-FU → FUMP
pathway by OPRT, another is the 5-FU → 5-fluorouridine
(FUrd) → FUMP pathway via uridine phosphorylase and
uridine kinase, and yet another is the 5-FU → 5-fluoro-
deoxyuridine (FdUrd) → FdUMP pathway via thymidine
phosphorylase and thymidine kinase.
TS is an enzyme that catalyses conversion of 2'-
deoxyuridine-5'-monophosphate to 2'-deoxythymidine-5'-
monophosphate. An active metabolite of fluorouracil, 5'-
fluorodexyuridinylate, forms stable ternary complexes
with TS and folate cofactor, thereby preventing DNA.
Cases with a low TS protein expression level tended to
have a high antitumor efficacy of S-1 in oral squamous cell
carcinoma [12], and no significant difference has been re-
ported when the differentiated type, gender and stage were
studied with immunostaining [7]. Other reports have also
demonstrated no significant difference in the differentiated
type and stage when TS was measured with the DTP method
[15] while also showing cases with low TS values to have a
high antitumor efficacy [4]. It has been reported that if the
TS enzyme content in tumor cells is low, then the antitumor
effects of 5-FU are high in gastric cancer and colorectal can-
cer [3, 9, 10]. In this study, the result was similar, and cases
with low TS gene expression were responders in 9 of 10
cases. In addition the average values of TS gene expression
with the responders were lower than the expression with the
nonresponders. Regarding males who were less than 70
years of age, stage I and II, well differentiated type and
tongue, the TS mRNA expression of the responders were
significantly lower than for the nonresponders. As a result,
the TS gene expression is thus considered to be a useful pre-
dictive factor.
It is believed that TP converts 5-FU into FdUMP, form-
ing a complex with TS, while also inhibiting TS enzymes
from causing DNA damage. For TP, in comparison to TS
Fig. 4. The labeling indices for TS, TP and OPRT proteins were determined by calculating the percentage of immunoreactive cells in cancer
cells according to response. The differences were not significant (Mann-Whitney U test).
Table 3. mRNA expression of TS, TP and OPRT accoding to response
Mann-Whitney’s U-test *p<0.05 **p<0.01, TS: thymidylate syn-
thase, TP: thymidine phosphorylase, OPRT: orotate phosphoribosyl
transferase.
Res: responders, Nonres: nonresponders.
Number of patients TS TP OPRT
Gender
Male 16 Res 7 2.3
**
44.8 0.8
*
Nonres 9 5.5 50.4 2.1
Female 4 Res 3 3.3 75.2 1.2
Nonres 1 2.3 42.8 0.3
Age (years)
≤70 11 Res 5 1.9
*
39.5 1
Nonres 6 5.5 43.9 2.4
>70 9 Res 5 3.3 68.3 0.9
Nonres 4 4.9 58.2 1.2
Clinical stage
I=4 18 Res 10 2.6
*
53.9 0.9
II=14 Nonres 8 5.3 48.1 2.1
III=1 2 Res 0
IV=1 Nonres 2 5 55.6 1.1
WHO classification
Well 15 Res 9 2.4
*
53.1 1
Nonres 6 4.9 65 1.5
Moderately 5 Res 1 4.3 61.5 0.7
Nonres 4 5.8 26.6 2.6
Site
Tongue 8 Res 3 1.6
*
41.1 0.9
Nonres 5 5.2 51.1 1.6
Upper gingiva 3 Res 2 3.3 87 1.3
Nonres 1 8.7 22.9 2.4
Lower gingiva 3 Res 0
Nonres 3 4.3 63.5 1.1
Buccal mucosa 5 Res 5 2.9 48.4 0.8
Nonres 0
Floor of mouth 1 Res 0
Nonres 1 4.8 27.3 5.1TS, TP and OPRT Levels as a Predictive Factor of Chemotherapy 45
and OPRT, studies on the effect on tumors are relatively
new, and such reports are very few. No difference in the TP
mRNA expression level due to the response in oral squa-
mous cell carcinoma has been reported [4]. While it is re-
ported that cases with high mRNA expression level of TP in
tumors have low effects of 5-FU therapy in metastatic colon
cancer [11], it is also reported that cases with a high TP ex-
pression have a better prognosis in subjects for postoperative
adjuvant chemotherapy [14]. In this study, the TP mRNA
expression in patients who were less than 70 years of age
were significantly lower than the expression in those older
than 71 years of age. The protein expression showed a simi-
lar tendency. This indicated that TP demonstrates differen-
tial expression, depending on age. There was no remarkable
difference in the mRNA and protein expression of TP due to
the response.
OPRT is an enzyme that converts fluorinated pyrimi-
dine series anticancer drugs into active nucleotides, which
are regarded as a main enzyme in the first step involved in
DNA and RNA inhibition. Therefore, if the OPRT activity
value is low, the metabolism of FdUMP does not progress,
and thus the antitumor effects of 5-FU are assumed to
decrease.
In this study, mRNA and protein expression tended to
be low in the response groups. OPRT mRNA of the male
responders was also significantly lower than for the non-
responders. Those findings were different from previous
expectations. This cannot be compared, because of the
small number of cases, but buccal mucosa cancer is in-
cluded in 5 of 10 cases in the response group (low in all 5
cases), and well-differentiated cases are included in 9 of
10 cases in the response group (low in 8 of 9 cases), and
therefore it can be assumed that OPRT expression of buccal
mucosa cancer or well-differentiated cases show less OPRT
expression. It has been reported that no significant difference
was observed when OPRT mRNA was measured and the
response was compared for oral squamous cell carcinoma
[4]. In colon cancer, there are reports that responding tumors
had a statistically higher OPRT gene expression than non-
responding tumors [2].
We expected to find differences in the numbers, but no
remarkable differences were found in Tables 2 and 3. This is
because there are only a small number of cases, hence it
would be desirable to study a greater number of cases in the
future.
In this study, the mRNA expression and protein expres-
sion showed similar trends but had slight differences in the
measured values. This may have been caused by differences
in the methods of quantitative and qualitative measurement.
Immunohistochemical staining, which is a simple procedure
that is inexpensive to perform, can visualize the expression
status of each enzyme, thereby distinguishing between inter-
stitial cells and tumor cells, but it is less quantitative. In ad-
dition, the conventional measurement of the level of mRNA
expression with reverse transcript-polymerase chain reac-
tions constitutes not only the level of expression of mRNA
in tumor cells but also the entire tumor tissue, including
tumor stroma, and the number of specimens was limited.
On the other hand, a method that selects tumor cells only in
the quantitative measurement of mRNA with DTP using the
specimens of formalin-fixed paraffin-embedded slices of
biopsy tissue as samples is a useful method. So far there
have only been a few studies published on the mRNA ex-
pression with the DTP method regarding oral cancer, and
therefore further study is still required. In this study, the
measurement of the TS levels using the DTP method may
potentially act as a predictive factor of antitumor effective-
ness. It is assumed that studies on the prognostic factors
in oral cancer and the predictive factors of the effect of 5-
FU-based drugs would make chemotherapy more effective
against oral cancer and therefore would have significance
in establishing a therapy that is suitable for individual oral
cancer patients.
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